Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

An assessment of the likely acceptability of vaginal microbicides for HIV prevention among women in rural Ghana.

Abdulai MA, Baiden F, Adjei G, Afari-Asiedu S, Adjei K, Tawiah C, Newton S.

BMC Womens Health. 2012 Nov 1;12:40. doi: 10.1186/1472-6874-12-40.

2.

Intravaginal practices and microbicide acceptability in Papua New Guinea: implications for HIV prevention in a moderate-prevalence setting.

Vallely A, Fitzgerald L, Fiya V, Aeno H, Kelly A, Sauk J, Kupul M, Neo J, Millan J, Siba P, Kaldor JM.

BMC Res Notes. 2012 Nov 1;5:613. doi: 10.1186/1756-0500-5-613.

3.

Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.

Doggett EG, Lanham M, Wilcher R, Gafos M, Karim QA, Heise L.

J Int AIDS Soc. 2015 Dec 21;18:20536. doi: 10.7448/IAS.18.1.20536. eCollection 2015. Review.

5.

Covert use, vaginal lubrication, and sexual pleasure: a qualitative study of urban U.S. Women in a vaginal microbicide clinical trial.

Hoffman S, Morrow KM, Mantell JE, Rosen RK, Carballo-Diéguez A, Gai F.

Arch Sex Behav. 2010 Jun;39(3):748-60. doi: 10.1007/s10508-009-9509-3. Epub 2009 Jul 28.

6.

The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial.

Morrow K, Rosen R, Richter L, Emans A, Forbes A, Day J, Morar N, Maslankowski L, Profy AT, Kelly C, Abdool Karim SS, Mayer KH.

J Womens Health (Larchmt). 2003 Sep;12(7):655-66.

PMID:
14583106
7.

Sexuality, HIV risk and potential acceptability of involving adolescent girls in microbicide research in Kisumu, Kenya.

Montandon M, Sahin-Hodoglugil NN, Bukusi E, Agot K, Boland B, Cohen CR.

Sex Health. 2008 Dec;5(4):339-46.

PMID:
19061553
8.

Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.

Rosen RK, Morrow KM, Carballo-Diéguez A, Mantell JE, Hoffman S, Gai F, Maslankowski L, El-Sadr WM, Mayer KH.

J Womens Health (Larchmt). 2008 Apr;17(3):383-92. doi: 10.1089/jwh.2006.0325.

PMID:
18328009
9.

Acceptability of a microbicide among women and their partners in a 4-country phase I trial.

Bentley ME, Fullem AM, Tolley EE, Kelly CW, Jogelkar N, Srirak N, Mwafulirwa L, Khumalo-Sakutukwa G, Celentano DD.

Am J Public Health. 2004 Jul;94(7):1159-64.

10.

Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing.

Braunstein S, van de Wijgert J.

J Womens Health (Larchmt). 2005 Jun;14(5):424-33. Review.

PMID:
15989415
11.

Women's interest in vaginal microbicides.

Darroch JE, Frost JJ.

Fam Plann Perspect. 1999 Jan-Feb;31(1):16-23.

12.

Microbicide acceptability among female sex workers in Beijing, China: results from a pilot study.

Han L, Lv F, Xu P, Zhang G, Juniper NS, Wu Z.

J Womens Health (Larchmt). 2009 Sep;18(9):1377-84. doi: 10.1089/jwh.2008.1239.

13.

The role of partnership dynamics in determining the acceptability of condoms and microbicides.

Montgomery CM, Lees S, Stadler J, Morar NS, Ssali A, Mwanza B, Mntambo M, Phillip J, Watts C, Pool R.

AIDS Care. 2008 Jul;20(6):733-40. doi: 10.1080/09540120701693974.

PMID:
18576176
14.

Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand.

Whitehead SJ, McLean C, Chaikummao S, Braunstein S, Utaivoravit W, van de Wijgert JH, Mock PA, Siraprapasiri T, Friedland BA, Kilmarx PH, Markowitz LE.

PLoS One. 2011;6(9):e14831. doi: 10.1371/journal.pone.0014831. Epub 2011 Sep 7.

15.

Microbicide preference among young women in California.

Holt BY, Morwitz VG, Ngo L, Harrison PF, Whaley KJ, Pettifor A, Nguyen AH.

J Womens Health (Larchmt). 2006 Apr;15(3):281-94.

PMID:
16620187
16.

Engaging male partners in women's microbicide use: evidence from clinical trials and implications for future research and microbicide introduction.

Lanham M, Wilcher R, Montgomery ET, Pool R, Schuler S, Lenzi R, Friedland B.

J Int AIDS Soc. 2014 Sep 8;17(3 Suppl 2):19159. doi: 10.7448/IAS.17.3.19159. eCollection 2014.

17.

Acceptability of formulations and application methods for vaginal microbicides among drug-involved women: results of product trials in three cities.

Hammett TM, Mason TH, Joanis CL, Foster SE, Harmon P, Robles RR, Finlinson HA, Feudo R, Vining-Bethea S, Jeter G, Mayer KH, Doherty-Iddings P, Seage GR 3rd.

Sex Transm Dis. 2000 Feb;27(2):119-26.

PMID:
10676980
18.

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.

Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, Mlisana KP, Maarschalk S, Arulappan N, Grobler A, Sibeko S, Omar Z, Gengiah TN, Mlotshwa M, Samsunder N, Karim SS.

Trials. 2011 Mar 7;12:67. doi: 10.1186/1745-6215-12-67.

19.

Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.

Govender EM, Mansoor LE, Abdool Karim Q.

AIDS Care. 2017 Jun;29(6):734-740. doi: 10.1080/09540121.2016.1248349. Epub 2016 Nov 1.

PMID:
27799005
20.

Re-framing microbicide acceptability: findings from the MDP301 trial.

Montgomery CM, Gafos M, Lees S, Morar NS, Mweemba O, Ssali A, Stadler J, Pool R; MDP Team.

Cult Health Sex. 2010 Aug;12(6):649-62. doi: 10.1080/13691051003736261.

PMID:
20397079

Supplemental Content

Support Center